In Adult Acute Lymphoblastic Leukemia (ALL) Different Minimal Residual Disease (MRD) Levels Predict Clinical Outcome in All Patients and Response to Allogeneic/Autologous Transplantation in MRD-Positive Patients.
Renato Bassan(Pittini Group (Italy)), Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Orietta Spinelli(Ospedale Papa Giovanni XXIII), Elena Oldani(Ospedale Papa Giovanni XXIII), Fabio Ciceri(Vita-Salute San Raffaele University), Erika Borlenghi(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Vincenzo Cassibba, Claudio Romani(Azienda Ospedaliera G. Brotzu), Barbara Peruta(Ospedale Papa Giovanni XXIII), Tamara Intermesoli(University of Bergamo), Agostino Cortelezzi(University of Milan), Giacomo Gianfaldoni, Ernesta Audisio(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Enrico Maria Pogliani(Azienda Ospedaliera San Gerardo), Manuela Tosi(Ospedale Papa Giovanni XXIII), Daniele Mattei, Eros Di Bona(San Antonio College), Anna Maria Scattolin(Ospedale dell' Angelo)
Cited by 1
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Gene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency
|New England Journal of Medicine|2009|1k
The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study.
|PubMed|2006|909
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
|Nature Genetics|2019|627